Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Total Non-Current Liabilities (2021 - 2025)

Stoke Therapeutics has reported Total Non-Current Liabilities over the past 5 years, most recently at $8.1 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 226.96% year-over-year to $8.1 million; the TTM value through Dec 2025 reached $8.1 million, up 226.96%, while the annual FY2025 figure was $8.1 million, 226.96% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $8.1 million at Stoke Therapeutics, down from $10.4 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $53.1 million in Q1 2022 and troughed at $2.5 million in Q4 2024.
  • A 5-year average of $26.9 million and a median of $29.2 million in 2024 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 908.46% in 2022 and later tumbled 93.47% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $3.9 million in 2021, then soared by 908.46% to $39.8 million in 2022, then dropped by 4.69% to $38.0 million in 2023, then tumbled by 93.47% to $2.5 million in 2024, then skyrocketed by 226.96% to $8.1 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for STOK at $8.1 million in Q4 2025, $10.4 million in Q3 2025, and $10.9 million in Q2 2025.